Wuxi XDC Valuation Multiples

Wuxi XDC Overview

About Wuxi XDC

WuXi XDC Cayman Inc is a CRDMO focused on the ADC and broader bioconjugate market and is the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, it offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development, and manufacturing. The company provides these services from proximately located laboratories and manufacturing facilities, resulting in the reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development, and manufacturing platform, its mission is to continuously enhance its platform and propel and transform the development of the bioconjugate industry.

Founded

2020

HQ

Employees

2.0K

Website

wuxixdc.com

Sectors

BiopharmaceuticalsContract Research & ManufacturingBioTech

Financials (LTM)

Revenue: $960M

EBITDA: $301M

EV

$9B

Valuation Multiples

Multiples.vc

Start free trial

Wuxi XDC Financials

Wuxi XDC reported last 12-month revenue of $960M and EBITDA of $301M.

In the same LTM period, Wuxi XDC generated $346M in gross profit, $301M in EBITDA, and $241M in net income.

Wuxi XDC P&L

In the most recent fiscal year, Wuxi XDC reported revenue of $594M and EBITDA of $195M.

Wuxi XDC expects next 12-month revenue of XXX and NTM EBITDA of XXX

Wuxi XDC Stock Performance

Wuxi XDC has current market cap of $10B, and enterprise value of $9B.

Wuxi XDC's stock price is $7.71.

Wuxi XDC Valuation Multiples

Wuxi XDC trades at 9.1x EV/Revenue multiple, and 29.1x EV/EBITDA.

Wuxi XDC Financial Valuation Multiples

As of April 19, 2026, Wuxi XDC has market cap of $10B and EV of $9B.

Equity research analysts estimate Wuxi XDC's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Wuxi XDC has a P/E ratio of 40.3x.

Wuxi XDC Margins & Growth Rates

Wuxi XDC's revenue in the last 12 month grew by 36%.

Wuxi XDC's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Wuxi XDC's rule of 40 is 70% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Wuxi XDC's rule of X is 126% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Wuxi XDC Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.

Wuxi XDC M&A Activity

Wuxi XDC acquired XXX companies to date.

Last acquisition by Wuxi XDC was on XXXXXXXX, XXXXX. Wuxi XDC acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Wuxi XDC Investment Activity

Wuxi XDC invested in XXX companies to date.

Wuxi XDC made its latest investment on XXXXXXXX, XXXXX. Wuxi XDC invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).